{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:56:26Z","timestamp":1780448186490,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The mRNA vaccine BNT162b2 (Comirnaty, BioNTech\/Pfizer) and the vaccine candidate CVnCoV (Curevac) each encode a stabilized spike protein of SARS\u2010CoV2 as antigen but differ with respect to the nature of the mRNA (modified versus unmodified nucleotides) and the mRNA amount (30\u00a0\u03bcg versus 12\u00a0\u03bcg RNA). This study characterizes antisera elicited by these two vaccines in comparison to convalescent sera.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sera from BNT162b2 vaccinated healthcare workers, and sera from participants of a phase I trial vaccinated with 2, 4, 6, 8, or 12\u00a0\u03bcg CVnCoV and convalescent sera from hospitalized patients were analyzed by ELISA, neutralization tests, surface plasmon resonance (SPR), and peptide arrays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>BNT162b2\u2010elicited sera and convalescent sera have a higher titer of spike\u2010RBD\u2010specific antibodies and neutralizing antibodies as compared to the CVnCoV\u2010elicited sera. For all analyzed sera a reduction in binding and neutralizing antibodies was found for the lineage B.1.351 variant of concern. SPR analyses revealed that the CVnCoV\u2010elicited sera have a lower fraction of slow\u2010dissociating antibodies. Accordingly, the CVnCoV sera almost fail to compete with the spike\u2010ACE2 interaction. The significance of common VOC mutations K417N, E484K, or N501Y focused on linear epitopes was analyzed using a peptide array approach. The peptide arrays showed a strong difference between convalescent sera and vaccine\u2010elicited sera. Specifically, the linear epitope at position N501 was affected by the mutation and elucidates the escape of viral variants to antibodies against this linear epitope.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data reveal differences in titer, neutralizing capacity, and affinity of the antibodies between BNT162b2\u2010 and CVnCoV\u2010elicited sera, which could contribute to the apparent differences in vaccine efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/all.15189","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T14:47:23Z","timestamp":1637851643000},"page":"2080-2089","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Analysis of BNT162b2\u2010 and CVnCoV\u2010elicited sera and of convalescent sera toward SARS\u2010CoV\u20102 viruses"],"prefix":"10.1111","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-4538","authenticated-orcid":false,"given":"Sascha","family":"Hein","sequence":"first","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Luise","family":"Herrlein","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Mhedhbi","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bender","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Haberger","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuka","family":"Benz","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Eisert","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Stingl","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacology University Hospital of RWTH  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dreher","sequence":"additional","affiliation":[{"name":"Department of Pneumology and Intensive Care Medicine RWTH Aachen University Hospital  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Oberle","sequence":"additional","affiliation":[{"name":"Division of Pharmacovigilance Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Schulze","sequence":"additional","affiliation":[{"name":"Robert\u2010Koch\u2010Institut, Influenza and Other Respiratory Viruses  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Mache","sequence":"additional","affiliation":[{"name":"Robert\u2010Koch\u2010Institut, Influenza and Other Respiratory Viruses  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Budt","sequence":"additional","affiliation":[{"name":"Robert\u2010Koch\u2010Institut, Influenza and Other Respiratory Viruses  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hildt","sequence":"additional","affiliation":[{"name":"Main\u2010Kinzig\u2010Kliniken, Herzbachweg  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7688-236X","authenticated-orcid":false,"given":"Thorsten","family":"Wolff","sequence":"additional","affiliation":[{"name":"Robert\u2010Koch\u2010Institut, Influenza and Other Respiratory Viruses  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Hildt","sequence":"additional","affiliation":[{"name":"Department of Virology Paul\u2010Ehrlich\u2010Institute  Langen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576622"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007236"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2180-5"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.12.001"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01480-7"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198454"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4490"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9040349"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14868"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00311-w"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.03.043"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586"},{"key":"e_1_2_9_14_1","unstructured":"CureVac. CureVac Provides Update on Phase 2b_3 Trial of First\u2010Generation COVID\u201019. CVnCoV. Curevac. 2021."},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","unstructured":"CromerD ReynaldiA SteainM TriccasJA DavenportMP KhouryDS.Relating in vitro neutralisation level and protection in the CVnCoV (CUREVAC).;2021.trial: medRxiv: the preprint server for health sciences","DOI":"10.1101\/2021.06.29.21259504"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5"},{"key":"e_1_2_9_17_1","first-page":"1","article-title":"Efficacy and Safety of the CVnCoV SARS\u2010CoV\u20102 mRNA Vaccine Candidate: Results from Herald, a Phase 2b\/3, Randomised, Observer\u2010Blinded, Placebo\u2010Controlled Clinical Trial in Ten Countries in Europe and Latin America","author":"Kremsner PG","year":"2021","journal-title":"SSRN Electronic Journal"},{"key":"e_1_2_9_18_1","unstructured":"AmanatF StadlbauerD StrohmeierS NguyenTHO ChromikovaV McMahonM et al. A serological assay to detect SARS\u2010CoV\u20102 seroconversion in humans. medRxiv: the preprint server for health sciences 2020."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2020.05.015"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja00897a025"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381344"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2380-z"},{"key":"e_1_2_9_23_1","first-page":"1","article-title":"Safety and immunogenicity of an mRNA\u2010lipid nanoparticle vaccine candidate against SARS\u2010CoV\u20102: A phase 1 randomized clinical trial","author":"Kremsner PG","year":"2021","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.045"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","unstructured":"Gebre MS Rauch S Roth N Yu J Chandrashekar A Mercado NB et al. Optimization of Non\u2010Coding Regions Improves Protective Efficacy of an mRNA SARS\u2010CoV\u20102 Vaccine in Nonhuman Primates: bioRxiv: the preprint server for sciences 2021.","DOI":"10.1101\/2021.08.13.456316"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109415"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042521"},{"key":"e_1_2_9_29_1","unstructured":"Roth N Sch\u00f6n J Hoffmann D Thran M Thess A Mueller SO et al. CV2CoV an enhanced mRNA\u2010based SARS\u2010CoV\u20102 vaccine candidate supports higher protein expression and improved immunogenicity in rats 2021."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24339-7"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.15189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T08:57:13Z","timestamp":1692262633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/all.15189"],"URL":"https:\/\/doi.org\/10.1111\/all.15189","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"2021-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}